Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
about
The "Sticky Patch" Model of Crystallization and Modification of Proteins for Enhanced Crystallizability.Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptaseStructure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants.Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1.A stereo configuration-activity study of 3-iodo-4-(2-methylcyclohexyloxy)-6-phenethylpyridin-2(2H)-ones as potency inhibitors of HIV-1 variants.Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection.Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1.Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography.Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility.Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents.Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-]pyrimidine non-nucleoside inhibitorsAdvances in the development of pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors
P2860
Q30252224-C763DD48-249A-4EF4-BC4E-826635E71C9DQ36146704-BF26D74C-55CC-4260-BF7D-797CB892418BQ36167147-10CABA45-918F-4187-B301-23E6F288C92EQ38620336-30486751-D56A-4BF7-91F3-1B5AE090D17AQ38631098-22FFF2BF-7412-4C6E-8BA0-C11E06D23D39Q38811174-38416601-95ED-4F50-9A8D-00A6D5816EC1Q38975330-3EBD6EF5-ABEF-42EB-975B-259162F4AFB3Q39169967-E4F7563F-4669-4AE7-BE3D-2C1259065304Q40076123-7647F61A-DDFC-40DC-ABC2-7F4B393BAA9DQ41040182-A60C0FCC-E298-4772-97AD-E9ED1E590AC3Q47446122-5360C92B-7A02-480D-8197-69BCDBA5E6DDQ50317213-16D2352E-C96E-40EA-94C3-14A92797C982Q56531878-6A38A8BC-3538-4104-843C-1FD2ECD0C466Q57832765-16D92E6A-E1C3-450D-BF4C-8072EB9371E5
P2860
Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Structure-based evaluation of ...... everse transcriptase variants.
@ast
Structure-based evaluation of ...... everse transcriptase variants.
@en
type
label
Structure-based evaluation of ...... everse transcriptase variants.
@ast
Structure-based evaluation of ...... everse transcriptase variants.
@en
prefLabel
Structure-based evaluation of ...... everse transcriptase variants.
@ast
Structure-based evaluation of ...... everse transcriptase variants.
@en
P2093
P2860
P356
P1476
Structure-based evaluation of ...... everse transcriptase variants.
@en
P2093
David E Puleo
Karen S Anderson
Kathleen M Frey
Krasimir A Spasov
Mariella Bollini
P2860
P304
P356
10.1021/JM501908A
P407
P577
2015-03-05T00:00:00Z